Biomarin Pharmaceutical Inc. (BMRN)

Market Closed

24 Feb, 20:00

NASDAQ (NGS)

62. 62

-0.3

-0.48%

12.31B Market Cap

126.18 P/E Ratio

- Div Yield

3,264,412 Volume

1 Eps

$ 62.92

Previous Close

Day Range

59.63 66.28

Year Range

50.76 73.51

Want to track BMRN and more in your Portfolio? 🎯

Get Started For Free

BMRN earnings report is expected in 1 days (25 Feb 2026)

BioMarin (BMRN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks | 6 months ago

BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates

BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $1.44 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $0.96 per share a year ago.

Zacks | 6 months ago

BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth

BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 7 months ago

Looking for a Growth Stock? 3 Reasons Why BioMarin (BMRN) is a Solid Choice

BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market.

Zacks | 7 months ago

Wall Street Analysts Think BioMarin (BMRN) Could Surge 70.77%: Read This Before Placing a Bet

The consensus price target hints at a 70.8% upside potential for BioMarin (BMRN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks | 7 months ago